Enanta Pharmaceuticals (ENTA) EPS (Weighted Average and Diluted) (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported EPS (Weighted Average and Diluted) of -$0.45 for Q1 2026, up 57.55% on a YoY basis from -$0.29 in Q1 2025, and down 7.14% quarter-over-quarter from -$0.42 in Q4 2025.
Enanta Pharmaceuticals (ENTA) EPS (Weighted Average and Diluted) (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 15 years, with the latest figure at -$0.45 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 57.55% year-over-year to -$0.45; the trailing twelve-month figure through Mar 2026 stood at -$2.6 (up 42.73% YoY), and the FY2025 full-year result was -$3.84, up 29.93% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.45, down from -$0.42 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.42 in Q4 2025, with the low at -$1.86 in Q2 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.23 across 5 years, with a median of -$1.33 in 2023.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) slumped 49.54% — and 2025, when it surged 60.0%.
- Enanta Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.39 in 2022, then dropped by 13.67% to -$1.58 in 2023, then surged by 33.54% to -$1.05 in 2024, then surged by 60.0% to -$0.42 in 2025, then retreated by 7.14% to -$0.45 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.45 (Q1 2026), -$0.42 (Q4 2025), and -$0.88 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | -0.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.45 |
| Dec 31, 2025 | -0.42 |
| Sep 30, 2025 | -0.88 |
| Jun 30, 2025 | -0.85 |
| Mar 31, 2025 | -1.06 |
| Dec 31, 2024 | -1.05 |
| Sep 30, 2024 | -1.36 |
| Jun 30, 2024 | -1.07 |
| Mar 31, 2024 | -1.47 |
| Dec 31, 2023 | -1.58 |
| Sep 30, 2023 | -1.33 |
| Jun 30, 2023 | -1.86 |
| Mar 31, 2023 | -1.79 |
| Dec 31, 2022 | -1.39 |
| Sep 30, 2022 | -1.27 |
| Jun 30, 2022 | -1.53 |
| Mar 31, 2022 | -1.63 |
| Dec 31, 2021 | -1.48 |
| Sep 30, 2021 | -1.22 |
| Jun 30, 2021 | -1.19 |